EYPT analyst estimates

EyePoint (EYPT) analyst ratings, the average price target and its range, and every firm's latest call.

EYPT analyst ratings and price targets

DateFirmCallTarget
Oct 20, 2026Mizuho SecuritiesMizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'$0.50
Oct 20, 2026RBC CapitalEyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital$1.00
Oct 19, 2026JefferiesEyePoint downgraded to Hold from Buy at Jefferies$1.00
Sep 2, 2026China Renaissance Securities (US) Inc.TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold$4.00
Aug 18, 2026RBC CapitalEyePoint downgraded to Sector Perform from Outperform at RBC Capital$5.00
Aug 18, 2026Chardan CapitalEyePoint downgraded to Neutral from Buy at Chardan$5.00
Aug 17, 2026JefferiesEyePoint price target lowered to $8 from $30 at Jefferies$8.00
Aug 6, 2026H.C. WainwrightEyePoint price target lowered to $27 from $30 at H.C. Wainwright$27.00
Jul 29, 2026Mizuho SecuritiesEyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick'$39.00
Jul 15, 2026Stifel NicolausEyePoint initiated with a Buy at Stifel$40.00
Feb 19, 2026Mizuho SecuritiesEyePoint price target raised to $36 from $33 at Mizuho$36.00
Feb 5, 2026RBC CapitalRBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity'$39.00
Oct 29, 2025Mizuho SecuritiesEyePoint price target raised to $33 from $28 at Mizuho$33.00
Oct 20, 2025Mizuho SecuritiesMizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)$28.00
Nov 11, 2024H.C. WainwrightEyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright$22.00